Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) When Exposed to Plasma-derived Von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVIII) Concentrates: An Independent, International, Multicentre, Prospective, Controlled, Randomised, Open Label, Clinical Trial)

drug protocol number

ABB- 09 -001

drug sponsor

King Faisal Specialist Hospital & Research Centere

drug study

PLASMA DERIVED Factor VIII Recombinant FVIII

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh)

drug status

Ongoing

drug phase